Finance & valuation

Latest content

Key takeaways from Merck’s landmark covid IP licensing deal with the Medicines Patent Pool

The agreement is the first granting non-exclusive and royalty free rights to sub-licensees of a covid therapeutic or vaccine

02 November 2021

Flexibility crucial to growing appeal of big money drug royalty transactions, says leading deal-maker

In the wake of the firm’s latest $250 million investment, Sagard Healthcare Royalty Partners’ Ali Alagheband gives the inside track on life sciences IP-backed revenue sales

01 November 2021

Nokia Technologies boosts revenues and profits in strong Q3 patent licensing performance

Royalties grow on the back of new deals and renewals; company also shares new details on legal fight with Oppo, which does not appear to have significantly dimmed income outlook

29 October 2021

Hub and spoke IP strategies are generating billions of dollars in biopharma

New Crinetics spin-off is more evidence of the growing influence of models designed to monetise non-core life sciences assets

22 October 2021

Investment in medical device IP is surging

Diagnostic innovation buyouts drive resurgence of med-tech deal-making

19 October 2021

Ericsson turns in strong licensing quarter with Apple renewal looming

Continued impact of Samsung deal pushes Swedish company’s royalty take near $300 million – but executives warn upcoming re-negotiations could produce temporary disruption again

19 October 2021

Former Nortel and BlackBerry patents land with smartphone maker Honor

Transaction marks first outside patent acquisition since company was spun out from Huawei last year

13 October 2021

IPBC Europe in Dublin brought patent value issues to the fore

Saturday Opinion: A memorable two days in the Irish capital showed definitively that face-to-face trumps video and allowed for some detailed debate on key topics

09 October 2021

Four IP takeaways from Merck’s $11.5 billion Acceleron acquisition

Merck has struck the biggest life sciences M&A deal of 2021 so far. Here are the four key IP-related takeaways.

07 October 2021

Amgen’s Otezla win vindicates multi-billion-dollar IP purchase

US federal court victory sets up the $13.4 billion drug for exclusivity until 2028

05 October 2021

Get unlimited access to all IAM content